Literature DB >> 15948234

Inhibitory effect of adeno-associated virus-mediated gene transfer of human endostatin on hepatocellular carcinoma.

Hong Liu1, Cheng-Hong Peng, Ying-Bin Liu, Yu-Lian Wu, Zhi-Ming Zhao, Yong Wang, Bao-San Han.   

Abstract

AIM: To investigate the effect of adeno-associated virus-mediated gene transfer of human endostatin on the growth of hepatocellular carcinoma (HCC).
METHODS: HCC cell line Hep3B was infected with recombinant adeno-associated virus containing human endostatin gene (rAAV2-hEndo). The results of transfection were detected by RT-PCR and SDS-PAGE assay. MTT assay was used to observe the effects of supernatant of transfected cells on ECV304 cell proliferation. An animal model of HCC was established by injecting Hep3B cells subcutaneously into the back of nude mice. Intratumoral injection of rAAV2-hEndo, empty virus and phosphate-buffered saline were given sequentially. Serum endostatin was determined by ELISA, the inhibitory effect of endostatin on the growth of xenograft was assessed in 3 wk.
RESULTS: The results of RT-PCR and SDS-PAGE assay confirmed that rAAV2-hEndo successfully transfected Hep3B cells, and endostatin was secreted from Hep3B cells to medium. The supernatant of transfected cells markedly inhibited the proliferation of ECV304 cells (P<0.01). Intratumoral injection of rAAV2-hEndo (2 x 10(10) v.g.) led to a sustained serum endostatin level of approximately (86.71+/-5.19) ng/mL. The tumor volume and microvessel density were less in rAAV2-hEndo group than in control groups (P<0.01).
CONCLUSION: Human endostatin can be stably expressed by adeno-associated virus-mediated gene transfer and effectively inhibit the growth of HCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15948234      PMCID: PMC4315983          DOI: 10.3748/wjg.v11.i22.3331

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

Review 1.  Recombinant adeno-associated virus as delivery vector for gene therapy--a review.

Authors:  Yang Lu
Journal:  Stem Cells Dev       Date:  2004-02       Impact factor: 3.272

Review 2.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

3.  Endostatin induces endothelial cell apoptosis.

Authors:  M Dhanabal; R Ramchandran; M J Waterman; H Lu; B Knebelmann; M Segal; V P Sukhatme
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

4.  Endostatin inhibits murine colon carcinoma sinusoidal-type metastases by preferential targeting of hepatic sinusoidal endothelium.

Authors:  Miren S Solaun; Lorea Mendoza; Marco De Luca; Virginia Gutierrez; Mari-Paz López; Elvira Olaso; B Kim Lee Sim; Fernando Vidal-Vanaclocha
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

5.  Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas.

Authors:  O Musso; M Rehn; N Théret; B Turlin; P Bioulac-Sage; D Lotrian; J P Campion; T Pihlajaniemi; B Clément
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

6.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

Authors:  T Boehm; J Folkman; T Browder; M S O'Reilly
Journal:  Nature       Date:  1997-11-27       Impact factor: 49.962

7.  Antitumor interaction of short-course endostatin and ionizing radiation.

Authors:  N N Hanna; S Seetharam; H J Mauceri; M A Beckett; N T Jaskowiak; R M Salloum; D Hari; M Dhanabal; R Ramchandran; R Kalluri; V P Sukhatme; D W Kufe; R R Weichselbaum
Journal:  Cancer J       Date:  2000 Sep-Oct       Impact factor: 3.360

8.  Gene therapy delivery of endostatin enhances the treatment efficacy of radiation.

Authors:  Wenyin Shi; Christian Teschendorf; Nicholas Muzyczka; Dietmar W Siemann
Journal:  Radiother Oncol       Date:  2003-01       Impact factor: 6.280

9.  Serum levels of vascular endothelial growth factor, basic fibroblast growth factor and endostatin in human metastatic liver tumors.

Authors:  Masao Miyashita; Takashi Tajiri; Ken Yanagi; Tetsuya Shimizu; Ryohei Futami; Koji Sasajima; Akira Tokunaga
Journal:  Hepatogastroenterology       Date:  2003 Mar-Apr

10.  Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.

Authors:  Amir Abdollahi; Kenneth E Lipson; Axel Sckell; Heike Zieher; Frank Klenke; Daniel Poerschke; Alexandra Roth; Xiaohong Han; Martin Krix; Marc Bischof; Philip Hahnfeldt; Hermann-Josef Grone; Juergen Debus; Lynn Hlatky; Peter E Huber
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

View more
  4 in total

Review 1.  Gene therapy of liver cancer.

Authors:  Ruben Hernandez-Alcoceba; Bruno Sangro; Jesus Prieto
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

Review 2.  Treatment of human disease by adeno-associated viral gene transfer.

Authors:  Kenneth H Warrington; Roland W Herzog
Journal:  Hum Genet       Date:  2006-04-13       Impact factor: 4.132

3.  Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2: laboratory investigation.

Authors:  Oszkar Szentirmai; Cheryl H Baker; Szofia S Bullain; Ning Lin; Masaya Takahashi; Judah Folkman; Richard C Mulligan; Bob S Carter
Journal:  J Neurosurg       Date:  2008-05       Impact factor: 5.115

4.  A 3' UTR SNP in COL18A1 is associated with susceptibility to HBV related hepatocellular carcinoma in Chinese: three independent case-control studies.

Authors:  Xiaopan Wu; Jia Wu; Zhenhui Xin; Huifen Wang; Xilin Zhu; Liping Pan; Zhuo Li; Hui Li; Ying Liu
Journal:  PLoS One       Date:  2012-03-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.